Milestones

1. The public competitive project funded by MICIIN (PDC2022-133775-I00) led by Dr. Alicia Mansilla entitled "A new therapeutic strategy for Fragile X syndrome" has started.

2. Gomez-Sintes R, Xin Q, Jimenez-Loygorri JI, McCabe M, Diaz A, Garner TP, Cotto-Rios XM, Wu Y, Dong S, Reynolds CA, Patel B, de la Villa P, Macian F, Boya P, Gavathiotis E, Cuervo AM. Targeting retinoic acid receptor alpha-corepressor interaction activates chaperone-mediated autophagy and protects against retinal degeneration. Nat Commun. 2022; 13(1):4220. doi: 10.1038/s41467-022-31869-1. PMID: 35864098.

3. Ramirez-Pardo I, Villarejo-Zori B, Jimenez-Loygorri JI, Sierra-Filardi E, Alonso-Gil S, Mariño G, de la Villa P, Fitze PS, Fuentes JM, Garcia-Escudero R, Ferrington DA, Gomez-Sintes R, Boya P. Ambra1 haploinsufficiency in CD1 mice results in metabolic alterations and exacerbates age-associated retinal degeneration. Autophagy. 2023; 19(3):784-804. doi: 10.1080/15548627.2022.2103307. PMID: 35875981.

4. Sánchez-Cruz A, Hernández-Pinto A, Lillo C, Isiegas C, Marchena M, Lizasoain I, Bosch F, de la Villa P, Hernández-Sánchez C, de la Rosa EJ. Insulin receptor activation by proinsulin preserves synapses and vision in retinitis pigmentosa. Cell Death Dis. 2022; 13(4):383. doi: 10.1038/s41419-022-04839-0. PMID: 35444190;

5. Grant of a Health Research Project" (PI22/01588) led by Prof. De la Villa entitled "Preclinical therapeutic trial of photosensitive molecules in models of blindness" and funded by the ISCIII.